Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms 2Severe Combined Immunodeficiency 1Rectal Neoplasms 1Neuroblastoma 1Mucopolysaccharidosis I 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 128Leucovorin 120Oxaliplatin 101Irinotecan 89Bevacizumab 55Cetuximab 44Capecitabine 40Folfox protocol 29Panitumumab 22Colonoscopy 17Chemotherapy, Adjuvant 16Floxuridine 15Early Intervention, Educational 15Erlotinib Hydrochloride 13Surveys and Questionnaires 11IFL protocol 11Counseling 11Celecoxib 11Immunohistochemistry 10Gemcitabine 10Psychiatric Rehabilitation 9Methods 8Magnetic Resonance Spectroscopy 8Gene Expression Profiling 8Exercise 8Dexamethasone 8sargramostim 7Sorafenib 7Radiotherapy 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colonic Neoplasms × Biological Specimen Banks × Clear all
NCT01850654 2018-06-28

OCCPI

Ohio State University Comprehensive Cancer Center

Phase NA Completed
3,470 enrolled
GastrointestinalGynecologic

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡